About Endogenous retrovirus group K member 19 Pol protein
Endogenous retrovirus group K member 19 Pol protein (ERVK-19) is a protein
from Homo sapiens identified by UniProt accession
Q9WJR5, 959 residues long.
MolForge cross-references it against 0 known binders and
0 disease associations.
Target properties
| Protein name | Endogenous retrovirus group K member 19 Pol protein |
|---|
| UniProt accession | Q9WJR5 |
|---|
| Gene | ERVK-19 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 959 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9WJR5-F1 | alphafold | PREDICTED | 80.33 | — |
Amino-acid sequence (959 residues)
NKSKKRRNRV SFLGAATVEP PKPIPLTWKT EKPVWVNQWP LPKQKLEALH LLANEQLEKG HIEPSFSPWN SPVFVIQKKS GKWRMLTDLR AVNAVNAVIQ PMGPLQPGLP SLAMIPKDWP LIIIDLKDCF FTIPLAEQDC EKFAFTIPAI NNKEPATRFQ WKVLPQGMLN SPTICQTFVG RALQPVREKF SDCYIIHYID DILCAAEMKD KLIDCYTFLQ AEVANAGLAI ASDKIQTSTP FHYLEMQIEN RKIKPPKIEI RKDTLKTLND FQKLLGDINW IRPTLGIPTY AMSNLFSILR GDSDLNSKRM LTPEATKEIK LVEEKIQSAQ INRIDPLAPL QLLIFATAHS PTGIIIQNTD LVEWSFLPHS TVKTFTLYLD QMATLIGQTR LRIIKLCGND PDKIVVPLTK EQVRQAFINS GAWQIGLANF VGIIDNHYPK TKIFQFLKMT TWILPKITRR EPLENALTVF TDGSSNGKAA YTGPKERVIK TQYQSAQRAE LVAVITVLQD FDQPINIISD SAYVVQATRD VETALIKYSM DDQLNQLFNL LQQTVRKRNF PFYITHIRAH TNLPGPLTKA NEQADLLVSS ALIKAQELHA LTHVNVAGLK NKFDVTWKQA KDIVQHCTQC QVLHLPTQEA GVNPRGLCPN ALWQMDVTHV SSFGRLSYIH VTVDTYSHFI WATCQTGEST SHVKKHLLSC FAVMGVPEKI KTDNGPGYCS KAFQKFLSQW KISHTTGIPY NSQGQAIVER TNRTLKTQLV KQKEGGDSKE CTTPQMQLNL ALYTLNFLNI YRNQTTTSAE QHLTGKKNSP HEGKLIWWKD NKNKTWEIGK VITWGRGFAC VSPGENQLPV WIPTRHLKFY NEPIGDAKKS TSAETETPQS STVDSQDEQN GDVRRTDEVA IHQESRAADL GTTKEADAVS YKISREHKGD TNPREYAACG LDDCINGGKS PYACRSSCS
Explore Endogenous retrovirus group K member 19 Pol protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets